iFIT Lunch & Learn Session with Dr. Christoph Trautwein
Multi-modal metabolomics by NMR spectroscopy, timsTOF mass spectrometry and MALDI Imaging for deep metabolic phenotyping of human cancer
On behalf of the iFIT spokespersons Lars Zender, Juliane Walz and Bernd Pichler, it is our pleasure to inform you about and invite you to the first episode of our iFIT Lunch & Learn Session 2025 that will take place
on Wednesday, April 9th at 12:00 pm (CEST)
at Big Lecture Hall in the Medizinische Klinik (Otfried-Müller-Straße 10 , 72076 Tübingen ).
Our speaker, Dr. Christoph Trautwein (M3 Research Center, Tübingen ) will give a talk on
“Multi-modal metabolomics by NMR spectroscopy, timsTOF mass spectrometry and MALDI Imaging for deep metabolic phenotyping of human cancer”.
Recent advances in cancer research such as new imaging probes or peptide vaccines are enabling us to characterize tumour features non-invasively and to foster personalized treatment strategies. But how can we make sure cancer treatment is efficient? Or could we even diagnose cancer in a simple biofluid sample long before it metastasises? Could we learn from a tumour biopsy which metabolic pathways offer promising complementary therapy targets? And how could we do all of that not only for one but hundreds of patients with high-throughput and reasonable costs?.
In the postgenomic era, metabolomics is emerging as a key science for personalized precision medicine by using absolute concentrations and spatial distribution changes of metabolites and lipids to detect cancer onset, monitor treatment outcome and side effects, taking advantage of the steadily increasing knowledge how small molecules drive health and disease.
In this talk I will introduce to metabolomics science in the realms of cancer research. I will illustrate how we employ quantitative NMR spectroscopy to develop blood-based biomarker panels to stratify distinct solid cancers, how we use trapped ion mobility spectrometry time of flight (timsTOF) mass spectrometry to uncover immune-modulating metabolites in cancer stool and ascites, and how we elucidate the tumour microenvironment with high-resolution MALDI Imaging on the single cell level. Our results show that the combination of latest metabolomics and lipidomics approaches has the potential to sustainably change the way how we detect, treat and even prevent cancer.
As a special feature of this program, the iFIT will sponsor free lunch packages! (First come, first serve)
All members of the University Hospital and University of Tübingen are invited to participate!
We look forward to this Lunch & Learn Session and to see you there!
